[go: up one dir, main page]

RU95101369A - Antiulcer agent - Google Patents

Antiulcer agent

Info

Publication number
RU95101369A
RU95101369A RU95101369/14A RU95101369A RU95101369A RU 95101369 A RU95101369 A RU 95101369A RU 95101369/14 A RU95101369/14 A RU 95101369/14A RU 95101369 A RU95101369 A RU 95101369A RU 95101369 A RU95101369 A RU 95101369A
Authority
RU
Russia
Prior art keywords
treatment
course
diseases
days
proposed
Prior art date
Application number
RU95101369/14A
Other languages
Russian (ru)
Other versions
RU2083203C1 (en
Inventor
В.Т. Зайцев
К.М. Резников
Э.В. Минаков
Н.М. Зяблова
Original Assignee
В.Т. Зайцев
К.М. Резников
Э.В. Минаков
Н.М. Зяблова
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by В.Т. Зайцев, К.М. Резников, Э.В. Минаков, Н.М. Зяблова filed Critical В.Т. Зайцев
Priority to RU95101369A priority Critical patent/RU2083203C1/en
Publication of RU95101369A publication Critical patent/RU95101369A/en
Application granted granted Critical
Publication of RU2083203C1 publication Critical patent/RU2083203C1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FIELD: medicine, gastroenterology, pharmacy. SUBSTANCE: invention proposes the use of synthetic purgative medicinal agents (phenolphthalein, isaphenin, isaman, bisacodyl, guttalax) with food obligatory. Treatment course is 14-28 days that can be prolonged at complicated disease form up to resistant remission. For prophylaxis course can be decreased to 7 days. Conventional treatment is incompatible with the proposed one. In the process of treatment water intake is 1.5-2.5 l per 24 h (or nonalcoholic beverage). Contraindication: cholelithiasis, complicated ulcer disease requiring surgery operation. EFFECT: enhanced effectiveness, decreased treatment period of gastroenteric diseases.

Claims (1)

Изобретение относится к гастроэнтерологии, а именно к базисным средствам для лечения заболеваний желудочно-кишечного тракта: гастритов, гастродуоденальных язв, сопутствующих холецистита, панкреатита, колита, а также для профилактики рецидивов этих болезней. Цель изобретения - повышение эффективности и сокращение сроков лечения гастритов, гастродуоденальных язв, сопутствующих холецистита, панкреатита, колита, профилактика рецидивов этих болезней. Для достижения этой цели предлагается использовать синтетические слабительные лекарственные средства (фенолфталеин, изафенин, изаман, бисакодил, гутталакс) строго обязательно с каждым приемом пищи любого из этих медикаментов в разовых дозах, разрешенных Минздравом. Курс лечения 14-28 дней, при осложненной и длительной формах заболеваний курс лечения продлевается до достижения стойкой ремиссии. Для профилактики рецидива заболеваний курс лечения может быть сокращен до 7 дней. Не совместимо традиционное лечение с предлагаемым. При лечении обязателен прием 1,5 - 2,5 л воды в сутки (или безалкогольных напитков). Противопоказанием к предлагаемой терапии является холелитиаз с размером конкрементов более 2-3 мм., осложненное течение язвенной болезни, требующее хирургического лечения.The invention relates to gastroenterology, and in particular to basic agents for the treatment of diseases of the gastrointestinal tract: gastritis, gastroduodenal ulcers, concomitant cholecystitis, pancreatitis, colitis, as well as for the prevention of relapse of these diseases. The purpose of the invention is to increase the efficiency and shorten the treatment of gastritis, gastroduodenal ulcers, concomitant cholecystitis, pancreatitis, colitis, prevention of relapse of these diseases. To achieve this goal, it is proposed to use synthetic laxative drugs (phenolphthalein, isafenin, isaman, bisacodyl, guttalax) strictly required with each meal of any of these medicines in single doses permitted by the Ministry of Health. The course of treatment is 14-28 days, with complicated and prolonged forms of diseases, the course of treatment is extended until a stable remission is achieved. To prevent relapse, the course of treatment can be reduced to 7 days. Traditional treatment is not compatible with the proposed one. During treatment, it is mandatory to take 1.5 - 2.5 liters of water per day (or soft drinks). Contraindication to the proposed therapy is cholelithiasis with calculus size of more than 2-3 mm., Complicated course of peptic ulcer requiring surgical treatment.
RU95101369A 1995-01-31 1995-01-31 Antiulcer agent RU2083203C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU95101369A RU2083203C1 (en) 1995-01-31 1995-01-31 Antiulcer agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU95101369A RU2083203C1 (en) 1995-01-31 1995-01-31 Antiulcer agent

Publications (2)

Publication Number Publication Date
RU95101369A true RU95101369A (en) 1996-11-10
RU2083203C1 RU2083203C1 (en) 1997-07-10

Family

ID=20164415

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95101369A RU2083203C1 (en) 1995-01-31 1995-01-31 Antiulcer agent

Country Status (1)

Country Link
RU (1) RU2083203C1 (en)

Also Published As

Publication number Publication date
RU2083203C1 (en) 1997-07-10

Similar Documents

Publication Publication Date Title
Weissmann Aspirin
AU590578B2 (en) Treatment of non-ulcer dyspepsia with bismuth salts
JPS6234731B2 (en)
ATE243030T1 (en) ORAL PREPARATION FOR PROPHYLACTIC/THERAPEUTIC TREATMENT OF HELICOBACTOR SP. INFECTIONS
Penttilä et al. Effect of zinc sulphate on the absorption of tetracycline and doxycycline in man
RU95101369A (en) Antiulcer agent
WO1995025525A1 (en) The use of dimeticone for the local antibacterial therapy and/or the prevention and therapy of helicobacter pylori (hp) associated syndromes and infectious diseases
RU2221576C1 (en) Method for rehabilitating patients after cholecystectomy
WO2021187635A1 (en) Production of mixture for preventing and treating respiratory infectious diseases and viral pneumonia
Yang et al. Aeromonas hydrophila septicemia in acute hand injury: A case report
AU699199B2 (en) The use of dimeticone for the local antibacterial therapy and/or the prevention and therapy of helicobacter pylori (HP) associated syndromes and infectious diseases
RU2279882C1 (en) Endoscopic method for treating patients for gastroduodenal ulcers with derinate preparation
RU2089206C1 (en) Method for treating erosive gastritis
RU2187318C2 (en) Method of healing chronic gastritis and duodenum ulcer disease
RU2192867C2 (en) Method for treating the cases of peptic gastric and duodenal ulcer disease
RU2403925C1 (en) METHOD OF TREATING Helicobacter pylori ASSOCIATED CHRONIC EROSIVE GASTRITIS
RU2142773C1 (en) Pelotherapy
RU2191579C2 (en) Method of treatment of chronic gastritis and gastroduodenal ulcer associated with helicobacter pylori
Usmonovna PHARMACOTHERAPEUTIC PROPERTIES OF DRUGS USED IN THE TREATMENT OF GASTRIC ULCER
Lukie Current Medical Management of Peptic Ulcer Disease
RU2174000C1 (en) Method of treatment of patients with infectious diseases
Kearns The prevention of recurrence of urinary stone
RU94041584A (en) Method of ulcer disease treatment
RU2002121267A (en) METHOD FOR PREVENTION AND TREATMENT OF GASTRIC ULCERS IN ANIMALS
RU2053786C1 (en) Method of immunodeficiency state prophylaxis